

Howard A. Burris, III, MD

Curriculum Vitae

3322 West End Avenue, Suite 900, Nashville, Tennessee 37203 Ph: (615) 329-7274 Fax: (615) 340-1576 Email: howard.burris@scresearch.net

Education

B.S. Degree:	1977- 1981	B.S. of Science	United States Military Academy	West Point, New York
Medical/Graduate:	1981- 1985	Doctor of Medicine	University of South Alabama, College of Medicine	Mobile, Alabama
Intern:	1985- 1986	Categorical Medicine	Brooke Army Medical Center	Fort Sam Houston, Texas
Residency:	1986- 1988	Residency in Internal Medicine	Brooke Army Medical Center	Fort Sam Houston, Texas
Fellowship:	1988- 1991	Fellowship in Hematology/ Medical Oncology	Brooke Army Medical Center	Fort Sam Houston, Texas

Licensure/Certifications

Board Certification	1986		Diplomate of the National Board of Medical Examiners
Division of Health Related Boards	1987	Pennsylvania State Licensure	Medical Doctor
Board Certification	1988		Diplomate of the American Board of Internal Medicine
Division of Health Related Boards	1991	Texas State Licensure	Medical Doctor
Board Certification	1991	Recertification Completed in 2001	Diplomate of the American Board of Medical Oncology
Division of Health Related Boards	1997	Tennessee State Licensure	Medical Doctor
Board Certification	2001	Recertification Completed in 2011	Diplomate of the American Board of Medical Oncology
	2011	Certification valid through	Diplomate of the American

Practice Area

Oncology

Professional Employment

President, Clinical Operations	2012 - Present	Sarah Cannon	Nashville, Tennessee
Executive Director, Drug Development	2011- Present	Sarah Cannon Research Institute	Nashville, Tennessee
Chief Medical Officer	2006- Present	Sarah Cannon Research Institute	Nashville, Tennessee
Director of Drug Development	1997- 2010	Sarah Cannon Research Institute	Nashville, Tennessee
Associate	1997- Present	Tennessee Oncology, PLLC	Nashville, Tennessee
Director of Drug Development Program	1990- 1997	Brooke Army Medical Center (Oncology Service)	Fort Sam Houston, Texas
Associate Professor	1996- 1997	The University of Texas Health Science Center (Department of Medicine/Oncology)	San Antonio, Texas
Director of Clinical Research	1993- 1995	Cancer Therapy and Research Center of South Texas (Institute for Drug Development)	San Antonio, Texas
Associate Director of Clinical Research	1992- 1993	Cancer Therapy and Research Center of South Texas (Institute for Drug Development)	San Antonio, Texas
Assistant Professor	1991- 1996	The University of Texas Health Science Center at San Antonio (Department of Medicine/Oncology)	San Antonio, Texas
Staff (Hematology/Oncology Service)	1991- 1997	Brooke Army Medical Center (Department of Medicine)	Fort Sam Houston, Texas
Staff (Hematology/Oncology Service)	1991- 1997	Cancer Therapy and Research Center of South Texas	San Antonio, Texas
Clinical Instructor	1990- 1991	The University of Texas Health Science Center at San Antonio (Department of Medicine/Oncology)	San Antonio, Texas

Professional Associations

American Society of Clinical Oncology	Associate Member
American College of Physicians	Fellow
American Society of Hematology	Associate Member
Southwest Oncology Group	Associate Member
Southern Association for Oncology (Affiliation of Southern Medical Association)	Associate Member
International Association for the Study of Lung Cancer (IASLC)	Associate Member

Professional Honors

Phi Kappa Phi	1980	US Military Academy
Distinguished Military Graduate	1981	US Military Academy
Letter of Commendation	1986	Brooke Army Medical Center
John Carpenter Outstanding Research Award	Academic Year 1987- 1988	
Commander's Award for Outstanding Research (Honorable Mention)	1991	
Promotion to Major	1991	US Army
Meritorious Service Medal	1992	Brooke Army Medical Center
The Surgeon General's Physician Recognition Award	1994	
Meritorious Service Medal (w/oak leaf cluster)	1994	Brooke Army Medical Center
Fellow	Elected January 1995	American College of Physicians
Army Commendation Medal	1997	Operation Joint Endeavor (Bosnia)
Promotion to Lieutenant Colonel	1997	US Army
President	2001-2002	Southern Association for Oncology
Giant of Cancer Care Award	2014	OnLive

Professional Memberships

CTRC Clinical Practice Committee (Vice Chairman)	1991-1995
Institute for Drug Development Project Committee	1991-1996

Drug Development Program Committee (San Antonio Cancer Institute)	1992-1996
Clinical Investigations Committee (San Antonio Cancer Institute)	1992-1996
Board Member (Hospice S.A., Inc.)	1993-1996
Brooke Army Medical Center Institutional Review Board	1995-1997
Brooke Army Medical Center Clinical Investigations Committee	1995-1997
Board Member (Southern Association for Oncology)	1997-Present
Minnie Pearl Research Foundation Board	1998-Present
Board Member (Gilda's Club)	1998-Present
ASCO Program Training Committee	1999-2002
Centennial Medical Center Institutional Review Board	2000-Present
ASCO Clinical Practice Committee	2001-Present
ASCO Education Committee	2002-Present
ASCO Sponsorship Sub-Committee	2003-2005
ASCO Scientific Program Committee	2004-Present
ASCO Ethics Committee	2004-Present
ASCO Board of Directors Committee	2006-2009
ASCO Nominating Committee	2010-2013
ASCO Cancer Research Committee	2013 - Present

Publications

Manuscripts:

1. Wall, J., Burris, H., Von Hoff, D.D., Rodriguez, G., Kneuper-Hall, R., Shaffer, D., O'Rourke, T., Brown, T., Weiss, G., Clark, G., McVea, S., Brown, J., Johnson, R., Friedman, C., Smith, B., Mann, W., Kuhn, J.: A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every twenty-one days. *Anticancer Drugs* 3:337-345, 1992.
2. Burris, H.A., Rothenberg, M., Kuhn, J.G., Von Hoff, D.D.: Clinical trials with the topoisomerase I inhibitors. *Seminars in Oncology* 19:663-669,1992.
3. Burris, H.A., III, Hanauske, A.R., Johnson, R., Marshall, M.H., Kuhn, J.G., Hilsenbeck, S.G., Von Hoff, D.D.: Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony forming units *in vitro*. *J Nat'l Cancer Inst* 84:1816-1820, 1992.

5. Shaffer, D.W., Burris, H.A., O'Rourke, T.J.: Testicular relapse in adult acute myelogenous leukemia. *Cancer* 70:1541-1544, 1992.
6. Rinaldi, D.A., Lippman, S.M., Burris, H.A., III, Chou, C., Von Hoff, D.D., Hong, W. K.: Phase II study of 13-cis-retinoic acid and alpha-2a interferon in patients with advanced squamous cell lung cancer. *Anti-Cancer Drugs* 4:33-36, 1993.
7. Eckardt, J.R., Burris, H.A., Rothenberg, M., Von Hoff, D.D., Kuhn, J.: Topoisomerase-I inhibitors: Promising novel compounds. *Contemp Oncol* 3:47-60, 1993.
8. Burris, H., Irvin, R., Kuhn, J., Kalter, S., Smith, L., Shaffer, D., Fields, S., Weiss, G., Eckardt, J., Rodriguez, G., Vreeland, F., Bayssas, M., LeBail, N., Von Hoff, D.: A phase I clinical trial of taxotere given as either a 2-hour or as a 6-hour intravenous infusion. *J Clin Oncol* 11(5):950-958, 1993.
9. Shaffer, D.W., Smith, L. S., Burris, H.A., Clark, G.M., Eckardt, J.R., Fields, S.M., Weiss, G.R., Rinaldi, D.A., Bowen, K.J., Kuhn, J.G., Von Hoff, D.D.: A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony stimulating factor in patients with advanced malignancies. *Cancer Res* 53:5929-5933, 1993.
10. Rothenberg, M.L., Kuhn, J.G., Burris, H.A., III, Nelson, J., Eckardt, J.R., Tristan-Morales, M., Hilsenbeck, S.G., Weiss, G.R., Smith, L.S., Rodriguez, G.I., Rock, M.K., Terada, K., Von Hoff, D.D.: A phase I and pharmacokinetic trial of weekly CPT-11. *J Clin Oncol* 11(11):2194-2204, 1993.
11. Vukelja, S.J., Baker, W.J., Burris, H.A., III, Keeling, J.H., Von Hoff, D.D.: Pyridoxine hydrochloride therapy for palmar-plantar erythrodysesthesia associated with taxotere. (Letter) *J Nat'l Cancer Inst* 85(17):1432-1433, 1993.
12. Burris, H.A., III: The future of cytokines. *Oncology* (12) (suppl) 7:55-58, 1993.
13. Burris, H.A., III: Preclinical pharmacology and phase I clinical trials of paclitaxel. Proceedings from *Pharmaceutical Issues of Taxol*, University of Arizona, pp. 8-13, 1993.
14. Eckardt, J.R., Burris, H.A., III, Kuhn, J.G., Bissery, M.C., Klink-Alakl, M., Clark, G.M., Von Hoff, D.D.: Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units *in vitro*. *J Nat'l Cancer Inst*, 86 (1): 30-33, 1994.
15. Burris HA 3rd: Pharmaceutical issues of paclitaxel. Preclinical pharmacology and phase I clinical trials. *Ann Pharmacother* 28(5 Suppl): S7 – 10. Review, 1994.
16. Bowen, K., Fields, S., Burris, H.: Topoisomerase I inhibitors: a new class of anticancer agents. *Adv in Oncology* (10) 2:16-21, 1994.
17. Muggia F.M., Burris H.A. III: Clinical development of topoisomerase-interactive drugs. *Adv in Pharmacology* 29B:1-31, 1994.
18. Brown, T.D., O'Rourke, T.J., Kuhn, J.G., Craig, J.B., Havlin, K., Burris, H.A. III, Cagnola, J., Hamilton, J.M.,

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.